Close Menu

NEW YORK (GenomeWeb) – Personalis announced yesterday that it has priced its initial public offering of around 7.9 million shares of common stock at $17 per share.

The company has also granted the underwriters a 30-day option to purchase up to an additional 1.2 million shares at the public offering price, less underwriting discounts and commissions. If all the shares are sold, including the over-allotments, the company will raise about $154.9 million in gross proceeds.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.